London — GlaxoSmithKline (GSK) is collaborating on an experimental Covid-19 vaccine with Medicago, a biotechnology company partly owned by tobacco giant Philip Morris International.

The partnership will combine Medicago’s plant-based production platform with GSK’s adjuvants — substances that enhance the body’s immune response — the companies said on Tuesday. Human testing is due to start in mid-July, and the companies aim to make the vaccine available in the first half of 2021, if it’s successful...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.